TNF抑制剂治疗中轴型脊柱关节炎的真实世界证据:临床试验结果能否外推?
41%的TNFi启动者符合至少1项试验标准,试验参与者治疗应答率61.7%高于真实世界51.3%(差10.4%,95%CI 4.4%至16.5%),是否符合试验标准不影响应答。
要点
- 真实世界中仅41%的TNFi启动者符合至少1项相关临床试验入选标准。
- 试验参与者应答率61.7%,高于真实世界51.3%(差10.4%,95%CI 4.4%至16.5%)。
- 是否符合试验入选标准不影响治疗应答(差2.0%,95%CI -9.4%至13.4%)。
核心结论
- 真实世界中启动TNFi的中轴型脊柱关节炎患者治疗应答率低于临床试验报告,提示试验结果外推需谨慎并影响成本效益评估。
研究设计与样本
- 基于英国风湿病学会生物制剂注册中轴型脊柱关节炎队列(BSRBR-AS)的真实世界队列研究,纳入2420例未使用过TNFi的中轴型脊柱关节炎患者,数据来自临床记录与患者问卷。
主要发现
- 2420例BSRBR-AS参与者中34%启动TNFi,其症状持续时间更短(15年 vs 22年)但疾病活动度更高(BASDAI 6.4 vs 4.0;BASFI 6.2 vs 3.8)。
- 启动TNFi者中41%符合至少1项相关试验入选标准,该亚组疾病活动度更高(BASDAI 6.9 vs 6.1)且功能更差(BASFI 6.6 vs 6.0)。
- 试验参与者中61.7%报告治疗应答,而BSRBR-AS患者为51.3%(差10.4%,95%CI 4.4%至16.5%)。
- 是否符合试验入选标准不影响治疗应答(差2.0%,95%CI -9.4%至13.4%)。
关键数值与推荐
- 治疗应答率:试验参与者61.7% vs 真实世界51.3%,差10.4%(95%CI 4.4%至16.5%)。
- 符合与不符合试验标准的患者应答差2.0%(95%CI -9.4%至13.4%)。
临床怎么用
- 临床解读TNFi临床试验应答率时需考虑真实世界人群应答率较低,外推试验结果时应谨慎。
- 真实世界中启动TNFi的患者疾病活动度更高、功能更差,但试验入选标准与否不影响应答,提示不应仅凭试验标准筛选治疗对象。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management guidelines assume that results from clinical trials can be generalised, although seldom is data available to test this assumption. We aimed to determine the proportion of patients commencing tumour necrosis factor inhibition (TNFi) who would have been eligible for relevant clinical trials, and whether treatment response differs between these groups and the trials themselves. The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) recruited a real-world cohort of TNFi-naïve spondyloarthritis patients with data collection from clinical records and patient questionnaires. Participant characteristics were extracted from trials identified from a recent Health Technology Assessment of TNFi for ankylosing spondylitis/non-radiographic axial spondyloarthritis. Descriptive statistics were used to determine the differences, including treatment response, between BSRBR-AS participants who would/would not have been eligible for the clinical trials and with trial participants. Among 2420 BSRBR-AS participants, those commencing TNFi (34%) had shorter symptom duration (15 vs 22 years) but more active disease (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 6.4 vs 4.0; Bath Ankylosing Spondylitis Disease Functional Index (BASFI) 6.2 vs 3.8). Of those commencing TNFi, 41% met eligibility criteria for ≥1 of fourteen relevant trials; they reported higher disease activity (BASDAI 6.9 vs 6.1) and poorer function (BASFI 6.6 vs 6.0). 61.7% of trial participants reported a positive treatment response, vs 51.3% of BSRBR-AS patients (difference: 10.4%; 95% CI 4.4% to 16.5%). Potential eligibility for trials did not influence treatment response (difference 2.0%; -9.4% to 13.4%). Fewer patients in the real world respond to TNFi than is reported in the trial literature. This has important implications for the generalisability of trial results, and the cost-effectiveness of TNFi agents.
引用
- Jones GT, Dean LE, Pathan E, et al. Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? Ann Rheum Dis. 2020. PMID: 32327428. doi:10.1136/annrheumdis-2019-216841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。